CP-164

USE OF IVERMECTINE FOR STRONGYLOIDOSIS: AN APPROACH TO CLINICAL PRACTICE

<u>Á. Caballero Romero</u>¹, D. Blánque Martínez², I. Casas Hidalgo², . González Medina², M. Valle Corpas², C. García Fernández², C. Gómez Peña² J. Cabeza Barrera².¹

Unidad de Gestión Clínica de Farmacia de Granada Complejo Hospitalario Universitario San Cecilio y Virgen de las Nieves

BACKGROUND

Strongyloides stercolaris is one of the most common parasites in tropical areas. Nowadays, the treatment of such parasite is based on ivermectine. However, ivermectine is not commercialized in Spain. Hospital pharmacists are responsible for applying this treatment to patients, only after the elaboration of an exhaustive report. In this article, we have rewieved all the reports as well as classified the information in order to present our clinical practice.

PURPOSE


To present our clinical experience regarding the treatment of the strongyloidosis.

MATERIAL AND METHODS

Observational descriptive study. Dates of patients were obtained from their clinical history. Examinated variables: age, sex, nacionality, doses, diagnostic methods(ELISA and coproparasitologic test), coinfections, eosinophilia and inmunosuppressed patients.

RESULTS

Ivermectine was started to be used in February 2012.15 patients were analysed - 8 men and 7 women. The average age was 36. Nacionality:12 patients from Bolivia, 1 from Guinea-Konakri, 1 from Cuba and 1 with unknown nacionality. Posology: 1 oral dose of 200 mcg/kg/day of ivermectin during two days in 100% of patients. Both, ELISA test and coproparasitologic test, were applied in 100% and 86% respectively. ELISA test result was positive in 93.3% patients, whereas coproparasitologic test result was negative in 84.3%. Coinfections: chagas, toxocariasis, tuberculosis, schistosomiasis, intestinal amebiasis, uncinariasis and himinolepis. Before the treatment, the average of eosinophylia was 15.99%. However, after the treatment, it decreased to 4.67%. No patient was diagnosed with VIH-1 nor treated with corticosteroids.



coproparasitologic	test	

CONCLUSION

The decrease of eosinophilic cells reveals that ivermectine is effective for the treatment of strongiloidosis. As our study shows, most of the patients carry the coexistence of other parasitologic deseases also transmitted by fecal-oral cycle. Therefore, pharmaceutics could play an important role in the prevention of this type of deseases both, by ensuring an appropriate use of this drug as well as by providing some useful advices on healthy practices.

